REG - Arecor Therapeutics - Notice of Interim Results
RNS Number : 5963KArecor Therapeutics PLC03 September 2021Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
NOTICE OF INTERIM RESULTS
Cambridge, UK, 3 September 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its maiden Interim Results for the six months ended 30 June 2021 on Thursday 23 September 2021.
Sarah Howell, Chief Executive Officer, and Susan Lowther, Chief Financial Officer, will host a virtual briefing for analysts and investors at 11:00 AM on the day of the results.
For more details or to attend the virtual briefing, please contact arecor@consilium-comms.com
-ENDS-
For more information, please contact:
Arecor Therapeutics plc
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer
Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications
Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Tel: +44 (0) 20 7886 2500
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray
Tel: +44 (0) 20 3709 5700
Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNORBUGDCSDGDGBD
Recent news on Arecor Therapeutics
See all newsREG - Arecor Therapeutics - Notice of Results
AnnouncementREG - Arecor Therapeutics - Arecor presents positive AT278 data at EASD
AnnouncementRCS - Arecor Therapeutics - Arecor announces AT278 presentation at EASD 2024
AnnouncementREG - Arecor Therapeutics Calculus Capital Ltd - Holding(s) in Company
AnnouncementREG - Arecor Therapeutics Oxford Tech 2 VCT - Holding(s) in Company
Announcement